Active Cellular Targeting miRNA Oligonucleotide Therapeutics (ONTs) to Treat Metabolic Pandemics
Time: 11:00 am
day: Seminar A- AM tracks
Details:
- Discovery and validation of miR-22-3p as an excellent metabolic miRNA
- In silico, in vitro and in vivo validation of miR-22-3p antagomirs to treat obesity, MAFLD and related cardiometabolic disorders
- Current preclinical validation of Generation 2.5 miR-22-3p antagomirs for enhanced active targeted delivery of a greatly reduced therapeutic dose with an extended intracellular Mean Residence Time
